Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors
Unresectable Advanced Solid Tumors|Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
DRUG: Surufatinib|DRUG: Sintilimab|RADIATION: Short course radiotherapy
Progression-free Survival (PFS), A duration from the date of initial treatment to disease progression or death of any cause, From Baseline to primary completion date, about 24 months
Objective response rate (ORR), The incidence of confirmed complete response or partial response, From Baseline to primary completion date, about 24 months|Disease Control Rate, The incidence of complete response, partial response and stable disease, From Baseline to primary completion date, about 24 months|Overall survival (OS), From Baseline to primary completion date, about 24 months, From the time of enrollment to death caused by any reason|The incidence of adverse events, The safety and tolerability of Surufatinib will be evaluated based on adverse events data, From Baseline to primary completion date, about 24 months
An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors